“By combining the best attributes of large biomolecule therapeutics with those of classic small molecule drugs, Coferon seeks to establish a new class of orally bioavailable therapeutic molecules capable of hitting targets inside the cell with exquisite selectivity”

 

- Dr. Lee Arnold, VP and Chief Scientific Officer

 

Coferon, Inc. is a privately owned company that was founded in 2009 to reduce to practice the concept of self-assembling “coferons” pioneered by the Company’s three academic founders - Dr. Francis Barany and Dr. Maneesh Pingle at Weill-Cornell Medical College, and Dr. Don Bergstrom at Purdue University.  We seek to combine the best attributes of large biomolecule therapeutics with those of classic small molecule drugs by utilizing our proprietary bio-orthogonal linker chemistry. This technology enables the delivery of large molecular assemblies in component parts that are designed to self assemble on the target inside the cell - creating therapeutic molecules with enhanced size, potency and selectivity.  We are currently conducting research and development programs in the areas of epigenetic regulation (with an initial focus on the BRD family) and anti-infectives. The Company is based at the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York.